Clinical trialPhase 2Terminated
Irreversible Electroporation + Nivolumab for Patients With Metastatic Pancreatic Cancer
Irreversible Electroporation in Combination With Immune Checkpoint Inhibition, in Patients With Metastatic Pancreatic Cancer - A Prospective, Phase 2 Study
- Outcome
- Stopped earlyThe study was terminated on the basis on an evaluation of the safety and efficacy of the 9 included patients of which 2 of the patients were excluded before receiving any study treatments, thus 7 patients were treated in the study. (Toxicity)
- Phase
- Phase 2
- Status
- Terminated
- Study type
- Interventional
- Start
- 8 September 2022
- Ended
- 30 August 2023
- Enrollment
- 9 participants
- Sites
- 1
- Primary outcomes
- Incidence of treatment related adverse events [Safety and Tolerability]
- Sponsor type
- Academic / other
- Results posted
- No
- Last update
- 15 September 2023
These fields come from the trial’s registry entry. A summary of its population, design, endpoints and results, each tied to a quote, has not been written for this trial yet.
Ask this document
Answers come only from this document’s own text, as highlighted quotes. If it doesn’t say, you are told so instead of given a guess.
Try
Source text
Brief summary public domain (ClinicalTrials.gov)
The trial investigates the safety and efficacy of irreversible electroporation in combination with checkpoint inhibition in patients with metastatic pancreatic cancer.
Detailed description public domain (ClinicalTrials.gov)
The trial is designed as an investigator initiated prospective phase 2 study in patients with metastatic pancreatic cancer (PC) to determine the efficacy and safety of checkpoint inhibition administered concurrently with irreversible electroporation. A recently published preclinical study by Zhao et al. (2019) showed that the combination of IRE and PD-1-inhibitor suppressed the tumour growth and increased the survival of mice bearing pancreatic cancer. The aim of the trial is to initiate an abscopal response, leveraging the patient's immune system in eliciting a sufficient immune response.